- Open Access
Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment
© The Author(s). 2017
- Received: 25 August 2017
- Accepted: 1 November 2017
- Published: 13 November 2017
Colonization by the pathogen Clostridium difficile often occurs in the background of a disrupted microbial community. Identifying specific organisms conferring resistance to invasion by C. difficile is desirable because diagnostic and therapeutic strategies based on the human microbiota have the potential to provide more precision to the management and treatment of Clostridium difficile infection (CDI) and its recurrence.
We conducted a longitudinal study of adult patients diagnosed with their first CDI. We investigated the dynamics of the gut microbiota during antibiotic treatment, and we used microbial or demographic features at the time of diagnosis, or after treatment, to predict CDI recurrence. To check the validity of the predictions, a meta-analysis using a previously published dataset was performed.
We observed that patients’ microbiota “before” antibiotic treatment was predictive of disease relapse, but surprisingly, post-antibiotic microbial community is indistinguishable between patients that recur or not. At the individual OTU level, we identified Veillonella dispar as a candidate organism for preventing CDI recurrence; however, we did not detect a corresponding signal in the conducted meta-analysis.
Although in our patient population, a candidate organism was identified for negatively predicting CDI recurrence, results suggest the need for larger cohort studies that include patients with diverse demographic characteristics to generalize species that robustly confer colonization resistance against C. difficile and accurately predict disease relapse.
Clostridium difficile infection (CDI) is an urgent public health priority worldwide [1–5], and despite progress in infection control and innovative options for treatment of CDI, until recently, there has been a steady and considerable elevation in its incidence, as well as its reported severity of illness [2, 6–9]. Known factors associated with CDI include hospitalization, advanced age, antibiotic prescription, and gastrointestinal surgery, in addition to those less agreed upon such as proton pump inhibitor therapy [6, 9–14]. Standard management of CDI involves the administration of antibiotic therapy, such as metronidazole and vancomycin , but 22.4 and 14.2% of patients have been observed to have no response to metronidazole and vancomycin, respectively . Of the remaining patients with positive responses to antibiotic therapy, 30% have shown CDI relapses [7, 15, 17]. CDI relapses add a layer of complexity to CDI management, and currently available clinical models have limited power to predict the risk of recurrence, either before or after discontinuation of C. difficile treatment.
For patients with multiple failures of antibiotic treatment for recurrent infection, fecal microbiota transplantation (FMT) has become an effective treatment strategy (with 92% success rate ). FMT, which was performed as early as the fourth century , aims to restore normal microbiota , highlighting the crucially important role of the gut microbiome in providing C. difficile colonization resistance. Studies have shown that gut dysbiosis leads to reduced colonization resistance against C. difficile and ultimately increases susceptibility to CDI [21, 22]. More specifically, 16S rRNA gene sequence analyses have demonstrated that the bacterial diversity of patients with initial and recurrent CDI is noticeably lower than that of healthy subjects [23, 24]. Furthermore, higher relative abundances of Proteobacteria and Firmicutes phyla, along with a lower relative abundance of Bacteroidetes, have been reported in CDI patients . Researchers have begun investigating which specific bacterial signatures may be associated with CDI recurrence after treatment. For example, studies have associated elevated abundance of Enterobacteriaceae with increased susceptibility to recurrence [25–27]. More recently, positive associations between Veillonella, Streptococcus, Parabacteroides, and Lachnospiraceae and CDI recurrence have been suggested [22, 28].
Although the role of the gut microbiome in CDI susceptibility has been well established, the particular species contributing to recurrence likelihood remain unclear. Also, despite significant progress in our understanding of CDI and its recurrence, most studies have focused on static (single time point) features of the microbiome. The dynamics of the gut microbiome during treatment, and the association of these dynamic features with clinical/demographic factors, CDI severity, and recurrence, have not yet been scrutinized. Here, to fulfill the above gaps, we conducted the first prospective study along with a meta-analysis to uncover microbial signatures to predict recurrent CDI. Specific questions included: (1) are there any associations between severity of CDI, microbial or demographic features, and CDI recurrence and (2) can we use microbial or demographic features at the time of diagnosis, or after treatment, to predict CDI recurrence? The meta-analysis was done between our dataset and a recently published dataset  with similar sample collection, DNA extraction, primer selection, and sequencing methods. By applying standardized bioinformatics and statistical methods to these two independent studies, we aim to identify consistent biological signatures of CDI recurrence. These signatures may be useful targets for clinical diagnostics, helping to direct more effective treatments (e.g., FMT) to patients with a higher risk for CDI recurrence.
Study design and sample collection
Eligible male and female patient participants were identified at the State University of New York Downstate Medical Center (University Hospital of Brooklyn) and Kings County Hospital Center, Brooklyn, New York. Criteria for participation included Clostridium difficile infection (CDI) with clinically significant diarrhea symptoms (change in bowel movement habits with three or more liquid or uniformed stools within 24 h) along with confirmation by a positive laboratory stool test via stool polymerase chain reaction (PCR) or toxin B assays, as well as willingness to participate and the ability to maintain close follow-ups. All subjects signed an informed consent form prior to enrollment. Exclusion criteria for participation included history of inflammatory bowel disease (Crohn’s disease or ulcerative colitis) and total or subtotal colectomy.
A total of 31 individuals experiencing their first episode of CDI (median age 64.0 years, interquartile range 60.0–73.0; 51.6% female) were enrolled between March 2014 and April 2015. Participants were followed at regular intervals beginning at the time of diagnosis before the administration of antibiotics treatment (pre-treatment, n = 31), 2 days after the start of antibiotics treatment (post-treatment, n = 31), 7 days after the start of antibiotics treatment or at the time of discharge (whichever was earlier (pre-discharge, n = 18)), followed by the fourth stool samples collected 2 weeks after the start of antibiotics (4 days after treatment completion, post-discharge, n = 9). Severity of CDIs were assessed early in the course of the disease to adapt medical management using the University of Pittsburgh Medical Center (UPMC) Index (version 2) [29, 30], where a UPMC score lower than 2 indicated moderate CDI, and a score equal or greater than 2 indicated severe CDI. Treatment regimens for each patient were based on the Infectious Diseases Society of America (IDSA) guidelines. Specifically, vancomycin was used for patients having UPMC score equal or greater than 2, demonstrating signs of systemic toxicity with or without profuse diarrhea, or warranting an ICU admission. The rest of patients were treated with metronidazole.
At each sampling point, stool specimens were collected in standard specimen containers, aliquoted with sterile technique into RNAlater, and were flash-frozen at − 80 °C. We also included five stool samples from healthy donors, in order to compare diversity and composition of healthy subjects with patient participants.
Patient characteristics and clinical data including age, sex, diet, weight, height, immunosuppressive therapy, hospitalization within 3 months prior to CDI diagnosis, antibiotic treatment within 3 month prior to CDI diagnosis, PPI therapy, and ICU stay prior to CDI diagnosis, in addition to detailed laboratory metadata at the initial encounter were extracted from medical records and patient interviews. Two to 4 weeks after discharge, follow-up data including CDI treatment regimen and its recurrence were obtained. This protocol was approved by the Institutional Review Board (IRB) at State University of New York Downstate Medical Center and the Massachusetts Institute of Technology.
DNA extraction and sequencing protocols
Total genomic DNA was extracted from 500-mg stool samples using the PowerFecal DNA Isolation kit (Mo Bio Laboratories, Carlsbad, CA, USA), according to the manufacturer’s instructions with the following modifications to improve yields from difficult-to-lyse bacteria. An additional bead-beating step using Faster Prep FP120 (Thermo) at 6 m/s for 1 min was used instead of vortex agitation. Incubation with buffers C2 and C3 was increased to 10 min at 4 °C. Subsequently, quantity of extracted DNA samples were measured by a Qubit Fluorometer (Life Technologies, Carlsbad, CA, USA), and then, extracted DNA of samples were sent to MIT-BioMicroCenter for multiplexed amplicon library preparation, covering the 16S rRNA gene V4 region using a dual-index barcode protocol, followed by Illumina MiSeq 16S rRNA gene sequencing.
16S rRNA gene data analysis
Sequencing of the stool samples on Illumina MiSeq instrument generated 7,176,335 total raw sequencing reads. Raw reads were processed using the QIIME version 1.8.0  and custom Python scripts. Forward and reverse Illumina reads were joined, quality trimmed to a minimum PHRED score of 25, and then truncated to a length of 250; the lengths determined based on the mode of the read length distribution. Singleton reads were removed from the dataset, and chimeras were eliminated using the UPARSE-OTU algorithm . Closed reference OTU picking was employed by aligning unique reads to the GreenGenes OTU database, at 99% identity (May 2013 release) using the USEARCH algorithm [33, 34]. Representative sequences for each OTU were aligned using PyNast, with a minimum alignment overlap of 75 bp , and a phylogenetic tree was built using FastTree 2.0 . Of the 89 collected stool samples, a total of 6,754,571 high-quality sequence reads were identified, representing 6160 OTUs for downstream analyses. Relative abundances of different bacterial genera were obtained by collapsing 16S rRNA gene OTU taxonomies to the genus level and summing OTUs within the same genus. Finally, abundances of different bacterial families were obtained by collapsing 16S rRNA gene OTU taxonomies to the family level and summing OTUs within the same family. At each level, taxa occurring in only one sample as well as low abundance taxa, accounting for less than 0.05% of the total community were removed. This step reduced the total number of statistical tests that were performed and thus reduced the burden of multiple hypothesis testing. After filtering, 195 OTUs, 51 genera, and 16 families remained for downstream analyses.
Severity of CDIs were assessed early in the course of the disease to adapt medical management using the University of Pittsburgh Medical Center (UPMC) Index (version 2) , where a UPMC score equal or greater than 2 indicated severe CDI. Microbial relationships between disease severity index, infection recurrence, and other collected metadata were evaluated by Spearman correlation with a false discovery rate (FDR) correction.
Overall microbial community diversity (α-diversity) was measured using the Shannon entropy [18, 21, 22]. Significant difference in α-diversity between groups (patients with and without recurrence) was determined using the Mann-Whitney U test. Differences in community structure across samples (β-diversity) were calculated using the weighted UniFrac distance metric and visualized by Principal Coordinates Analysis (PCoA) plots using custom R scripts. Significant differences in β-diversity across patient groups were evaluated using Permutational Multivariate Analysis of Variance (PERMANOVA) with 104 permutations. We also performed Kruskal-Wallis tests using R between features of groups with and without recurrence. All p values were then adjusted using the FDR correction.
To test whether microbial community composition can predict recurrence after full treatment, we trained a random forest model on pre-treatment samples, at OTU, genus, and family levels. We evaluated their performance using leave-one-out cross-validation and scored the predictive power in a receiver operating characteristic (ROC) analysis. The discriminatory power of OTUs, genera, and families were calculated as the area under the ROC curve (AUC). To assess the random forest model constructed, study groups were shuffled randomly and 100 random forest classifications were computed. The out-of-bag error estimate was compared to the un-shuffled dataset using a one-sample Wilcoxon signed-rank test to assess the performance of the classification model.
Characteristics of the studies
DNA extraction protocol
Patients’ sex (%)
Khanna et al. 
PowerFecal DNA Isolation kit (Mo Bio)
Lower percentile, 36.9
Upper percentile, 65.1
Lower percentile, 23.1
Upper percentile, 30.6
Pakpour et al. (current)
PowerFecal DNA Isolation kit (Mo Bio)
Lower percentile, 60.0
Upper percentile, 73.0
Lower percentile, 20.4
Upper percentile, 31.7
Sequence data and sample metadata, shared by the original authors, were downloaded from the NCBI Sequence Read Archive (SRA, accession number: SRP087648). For the Khanna et al.  dataset, only patients that responded to primary treatment (with and without recurrence) were kept for the meta-analysis. In our dataset, because individuals were sampled at multiple time intervals, only samples at the pre-treatment stage were included in order to make the two datasets comparable. Also, because only forward reads were used in the Khanna et al. study, we also included only forward reads from our study in the meta-analysis. For each dataset, sequence reads were demultiplexed, followed by quality filtering (PHRED score of 25) and removing any reads containing ambiguous bases. For both studies, read lengths were truncated to 200 bp. Subsequently, the quality-filtered reads were pooled, followed OTU calling against a reference set of OTUs assembled at 99% similarity from the Greengenes database (May 2013 release), as described above. Tables at OTU, genus, and family levels were constructed, and finally at each level, low abundant taxa (covering < 0.05% of total OTUs) were removed.
β-Diversity was calculated using the weighted UniFrac distance metric, and significant differences across patient groups were evaluated using PERMANOVA. For predictive models, we trained a random forest model on each individual dataset as well as the combined (meta) dataset. We also built the model by training on one dataset and using the other for cross-validation. The discriminatory power of OTUs, genera, and families were calculated as the area under the ROC curve (AUC) in each case.
To determine whether OTUs, genera, or families could serve as biomarkers to classify patients with or without recurrence at the pre-treatment stage, we constructed three separate random forest (RF) classifiers. The OTU-level RF had an error rate of 0.35 with the area under the ROC curve (AUC) of 0.68 (Additional file 2). The predictability of the OTU RF model was found to be significantly greater than randomly shuffled data (Wilcoxon signed-rank test, p value = 0.026). This model ranked OTUs belonging to Veilonella dispar as the most important variables for predicting recurrence (Additional file 2).
At the genus and family levels, error rates were 0.37 and 0.38, with the AUC of 0.57 and 0.53, respectively (Additional file 2). Veillonella ranked first at the genus level (Additional file 2), and Veillonellaceae ranked first at the family level (Additional file 2); however, the models’ predictabilities were found to be not significantly different from randomized data (Wilcoxon signed-rank test, p value > 0.05).
Comparison of different random forest model predictions at three bacterial taxonomic levels
Most important variable
Our results are in general agreement with the prior consensus that healthy and robust gut microbiota are protective against C. difficile invasion [37–39]—often termed “colonization resistance” [40, 41]. Disruption of the indigenous microbiota by perturbations, such as through the administration of antibiotics, can alter the overall physicochemical environment of the gut and the concentration of microbial and host metabolites [23, 26, 42, 43], as well as host immunity [44–46]. Such alterations can, in turn, yield lower colonization resistance and make the gut vulnerable to germination and toxin production by indigenous C. difficile or invasion by exogenous C. difficile spores. We found that there were significant differences in the initial (pre-treatment) microbial community structure between patients who exhibited CDI recurrence and those who did not. Administration of antibiotics to treat the initial C. difficile infection resulted in large-scale changes in the gut microbial community, which made recurrent and non-recurrent post-treatment microbial communities much more similar to one another than to the healthy, untreated controls. We did not find any notable associations between gut flora and the risk of recurrent CDI after antibiotic administration. We hypothesize that patients who did not show recurrence were able to recover towards an invasion-resistant community configuration  compared to patients who showed infection recurrence, but the exact configuration of this invasion-resistant state remains unclear. The development of this invasion-resistant state could be related to the positive feedback between intestinal bacteria and the intestinal mucosa. For example, Johansson et al.  demonstrated the profound effect of indigenous gut microbiota on the dynamics of mucus layer development. We speculate that low diversity microbiota in recurrent CDI subjects may lead to alteration in their intestinal mucosa, which in turn can negatively influence the host modulating effect of gut microbiota and lead to infection relapse after full recovery. The ability to recover to an invasion-resistant community can also depend upon 7a-dehydroxylase activity and subsequently higher conversion rates of primary bile salts to secondary bile salts, which are inhibitory to the germination of C. difficile spores and protect against CDI [21, 26]. Finally, invasion resistance may also be achieved by the recovery of indigenous clostridia, which may exclude C. difficile by saturating its available niche space in the gut .
We developed random forest classification models using the microbiota data at different levels of taxonomic resolution. The only significant model was at the OTU level, which was able to differentiate, albeit not very reliably, between individuals with and without recurrent CDI; classification did not improve when the microbiota results were combined with patients’ clinical metadata. Our RF analysis identified several OTUs related to Veillonella dispar as the most important features for predicting CDI recurrence. These OTUs were significantly enriched in non-recurrent patients. At genus and family levels, members of Veillonellaceae and Lachnospiraceae were the top-ranked RF features. Our results support prior work suggesting a positive association between members of the Lachnospiraceae family and colonization resistance against CDI [23, 49], several members of which are butyrate-producing, anaerobic bacteria. Butyric acid is known to strengthen colonic defensive barriers by elevating antimicrobial peptide levels (AMPs) and mucin production [50, 51]. Our meta-analysis showed that technical variation between studies overshadowed the biological variation. The lack of full consistency between the two studies may also be rooted in the difference in the average age or ethnicity of the two cohorts (Table 1). In addition, no significant feature or model prediction was observed using the truncated sequences from our original analysis (i.e., truncated in order to match sequence lengths from the Khanna study). This clearly implies the necessity for longer sequence (≥ 250 bps) reads for differentiating between closely related but distinct bacterial taxa and subsequently for CDI classification models.
The present work showed that patients’ microbiota before antibiotic treatment can be predictive of disease relapse, but surprisingly, post-antibiotic microbial community is indistinguishable between patients that recur or not. While fecal microbiota transplantation (FMT) has been effective for CDI therapeutics, there is a widespread interest in designing microbial therapies that rely on pure cultures of bacteria and that target CDI recurrence with greater safety and efficacy. Such efforts require identification of the gut microbial species conferring invasion resistance against C. difficile. In our patient population of Afro-Caribbean descent, Veillonella dispar could be a candidate organism for negatively predicting CDI recurrence. However, this cannot yet be generalized to other patient populations with different demographic characteristics, signifying the need for larger cohort studies that include patients with diverse demographic characteristics.
The authors wish to acknowledge the great support provided by the Center for Microbiome Informatics and Therapeutics at MIT and SUNY Downstate Medical Center, Department of Medicine.
This project is supported in part by a grant from the Center for Microbiome Informatics and Therapeutics at MIT and SUNY Downstate Medical Center, Department of Medicine, Award 68436.
Conceptualization was carried out by SP, AB, RZ, AM, LAM, and EJA. Data curation was conducted by SP, AB, RZ, AM, SMG, and TG. Data analysis was performed by SP and SMG. Data validation and modeling was performed by SMG. SP prepared the original draft of the article and all co-authors participated in the review and editing of the manuscript. The project was supervised by EJA and LAM. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Written informed consent was obtained from participants at enrollment. This study was approved by the Institutional Review Board (IRB) at State University of New York Downstate Medical Center and the Massachusetts Institute of Technology.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kuijper EJ, Coignard B, Tull P, ESCMID Study Group for Clostridium difficile, European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.View ArticlePubMedGoogle Scholar
- Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2368–9.View ArticlePubMedGoogle Scholar
- Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis. 2009;48:568–76.View ArticlePubMedGoogle Scholar
- Cheng JW, Xiao M, Kudinha T, Xu ZP, Hou X, Sun LY, Zhang L, Fan X, Kong FR, Xu YC. The first two Clostridium difficile ribotype 027/st1 isolates identified in Beijing, China—an emerging problem or a neglected threat? Sci Rep. 2016;6:1–8.Google Scholar
- Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect. 2013;66:115–28.View ArticlePubMedGoogle Scholar
- Kola A, Wiuff C, Akerlund T, van Benthem BH, Coignard B, Lyytikainen O, Weitzel-Kage D, Suetens C, Wilcox MH, Kuijper EJ, et al. Survey of Clostridium difficile infection surveillance systems in Europe, 2011. Eur Secur. 2016;21:5–12.Google Scholar
- Kelly CP, LaMont JT. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359Google Scholar
- Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. Can Med Assoc J. 2012;184:37–42.View ArticleGoogle Scholar
- Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection. Intern Emerg Med. 2016;11:657–65.View ArticlePubMedGoogle Scholar
- Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Review of Gastroenterology & Hepatology. 2010;4:409–16.View ArticleGoogle Scholar
- Dos Santos-Schaller O, Boisset S, Seigneurin A, Epaulard O. Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy. Spring. 2016;5:1–5.Google Scholar
- Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107:1011–9.View ArticlePubMedGoogle Scholar
- Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012;87:1106–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Ther Adv Gastroenterol. 2014;7:72–86.View ArticleGoogle Scholar
- Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40:1–8.View ArticlePubMedGoogle Scholar
- McDonald LC, Coignard B, Dubberke E, Song XY, Horan T, Kutty PK, Ad Hoc Clostridium Difficile S. Recommendations for surveillance of Clostridium difficile associated disease. Infect Control Hosp Epidemiol. 2007;28:140–5.View ArticlePubMedGoogle Scholar
- Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi DS. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1466–71.View ArticlePubMedGoogle Scholar
- Zhang FM, Luo WS, Shi Y, Fan ZN, Ji GZ. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1755–5.Google Scholar
- Guo B, Harstall C, Louie T, van Zanten SV, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther. 2012;35:865–75.View ArticlePubMedGoogle Scholar
- Theriot CM, Koenigsknecht MJ, Carlson PE, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li JZ, Young VB. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:1–10.Google Scholar
- Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, Kashyap PC. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther. 2016;44:715–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51:2884–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435–8.View ArticlePubMedGoogle Scholar
- Schubert AM, Rogers MAM, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM, Schloss PD. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio. 2014;5:1–9.Google Scholar
- Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, Bry L, Clish CB, Alm E, Korzenik JR. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016;43:1142–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Investig. 2014;124:4182–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Antharam VC, McEwen DC, Garrett TJ, Dossey AT, Li EC, Kozlov AN, Mesbah Z, Wang GP. An integrated metabolomic and microbiome analysis identified specific gut microbiota associated with fecal cholesterol and coprostanol in clostridium difficile infection. PLoS One. 2016;11:1–23.Google Scholar
- Gujja D, Friedenberg FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther. 2009;29:635–42.View ArticlePubMedGoogle Scholar
- McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265–72.View ArticlePubMedGoogle Scholar
- Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996–98.Google Scholar
- Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460–2461.Google Scholar
- McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL, Knight R, Hugenholtz P. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6:610–8.View ArticlePubMedGoogle Scholar
- Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics. 2010;26:266–7.View ArticlePubMedGoogle Scholar
- Price MN, Dehal PS, Arkin AP. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5Google Scholar
- Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis. 1993;16:S214–8.View ArticlePubMedGoogle Scholar
- Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190:2505–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Buffie CG, Bucci V, Stein RR, McKenney PT, Ling LL, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517:205–U207.View ArticlePubMedGoogle Scholar
- Vanderwaaij D. Colonization resistance of the digestive tract—mechanism and clinical consequences. Nahrung/Food. 1987;31:507–17.View ArticleGoogle Scholar
- Van der Waaij D, Berghuis-de Vries JM, Lekkerkerk-van der Wees JEC. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg. 1971;69:405–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Wilson M. Microbial inhabitants of humans: their ecology and role in health and disease. New York: Cambridge University Press; 2005.Google Scholar
- Yap IKS, Li JV, Saric J, Martin FP, Davies H, Wang YL, Wilson ID, Nicholson JK, Utzinger J, Marchesi JR, Holmes E. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res. 2008;7:3718–28.View ArticlePubMedGoogle Scholar
- Wlodarska M, Willing B, Keeney KM, Menendez A, Bergstrom KS, Gill N, Russell SL, Vallance BA, Finlay BB. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect Immun. 2011;79:1536–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghosh S, Dai C, Brown K, Rajendiran E, Makarenko S, Baker J, Ma C, Halder S, Montero M, Ionescu VA, et al. Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2011;301:G39–49.View ArticlePubMedGoogle Scholar
- Johansson MEV, Jakobsson HE, Holmen-Larsson J, Schutte A, Ermund A, Rodriguez-Pineiro AM, Arike L, Wising C, Svensson F, Backhed F, Hansson GC. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe. 2015;18:582–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Fischbach MA, Segre JA. Signaling in host-associated microbial communities. Cell. 2016;164:1288–300.View ArticlePubMedPubMed CentralGoogle Scholar
- Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther Adv Gastroenterol. 2013;6:53–68.View ArticleGoogle Scholar
- Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB. Suppression of clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family lachnospiraceae. Infect Immun. 2012;80:3786–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. 1998;12:499–507.View ArticlePubMedGoogle Scholar
- Wong JMW, de Souza R, Kendall CWC, Emam A, Jenkins DJA. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235–43.View ArticlePubMedGoogle Scholar